New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.
Sagar Lonial, MD
Advertisement
Articles by Sagar Lonial, MD
Sagar Lonial, MD, chief medical officer, Winship Cancer Institute of Emory University and Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treating patients with myeloma.
Advertisement
Latest Updated Articles
Sagar Lonial Discusses Treating Patients With MyelomaDecember 23rd 2015
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer
2
Thoracic Oncology Advances and Toxicity Management
3
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
4
ASCO Releases First Living Guideline for Recurrent Ovarian Cancer Care
5